Sophia Abene

Long-term clinical and economic benefits of an inclusive national HCV program targeting mothers and infants, two often overlooked populations.

Theratechnologies' new tesamorelin formulation provides a simplified, long-acting dosing regimen to effectively manage excess abdominal fat in adults with HIV-associated lipodystrophy.

Study uncovers the role of ploidy plasticity in fungal adaptation to fungicides, highlighting risks for human health and agricultural systems.

Key updates from the Centers for Disease Control and Prevention on influenza activity, hospitalizations, pediatric deaths, and current trends across the United States.

Environmental contamination plays a larger role than previously recognized, prompting calls for updated infection control strategies

Sharmeen Roy, PharmD, BCPS, on artificial intelligence (AI) in improving decision-making, reducing adverse drug events on National Adverse Drug Event Awareness Day, and upcoming research on pediatric dosing at the the Congress of the European Society of Clinical Microbiology and Infectious Diseases.

Sharmeen Roy, PharmD, BCPS, discusses the role of AI, real-world evidence, and clinician oversight in optimizing medication dosing for ICU patients.

Sharmeen Roy, PharmD, BCPS, discusses the role of Bayesian dosing, therapeutic drug monitoring, and hospital resource allocation.

In a new study, Marc Ka-Chun Chong, PhD discusses the antiviral's impact on survival and hospitalization outcomes.

Ashraf S. Ibrahim, PhD, outlines safety studies and the potential of this antibody therapy for treating this rare fungal infection, which is seemingly becoming less rare.

Novavax’s COVID-19 vaccine, Merck’s RSV antibody, and Innoviva’s gonorrhea antibiotic await regulatory decisions this quarter.

Ashraf S. Ibrahim, PhD, details over 20 years of research on a spore-coating protein and the development of VX-01 to block fungal tissue invasion.

Ashraf S. Ibrahim, PhD, discusses how VX-01 prevents fungal invasion of blood vessels and enhances immune response in immunocompromised patients.

New 21-valent conjugate vaccine authorized to combat invasive pneumococcal disease and pneumonia in individuals aged 18 and older.

David Wohl, MD, explains the health risks of visceral fat and the role of treatments like Tesamorelin F8 in managing the condition.

David Wohl, MD, discusses the complexities of diagnosing and the importance of managing ectopic fat in HIV patients.

Heather Platt, MD, discusses Merck’s ongoing research into real-world effectiveness and cost-effectiveness and offers a preview of data to be presented at ESCMID 2025.

Studies highlight the role of home visits, chest radiography, and sputum monitoring in TB prevention and treatment outcomes.

A 26% rise in childhood tuberculosis cases underscores the need for strengthened global TB control efforts.

This week, recent studies include Mandimycin for resistant fungal infections, fluctuating hospital AMR rates, a 6-month HIV treatment, global challenges in hepatitis testing, and the start of a Lassa fever vaccine trial.

Studies presented included once-yearly lenacapavir formulations for PrEP, bictegravir outperforming darunavir in advanced HIV, Immunocore's IMC-M113V showing viral control and reservoir reduction, and more.

Whitney Hartlage, PharmD, explores the role of expanded UTI definitions and urinalysis interpretation in addressing antibiotic overuse.

Zhuo Shang, PhD’s discovery of mandimycin offers a potential solution to drug-resistant infections like Candida auris by targeting phospholipids in fungal membranes.

Amanda Truong, MD, PhD, provides her perspective on diagnosis, treatment, and environmental factors, considering her involvement in a recent human case.

Rachel A Bender Ignacio, MD, MPH explores safety, pharmacokinetics, and future directions for HIV treatment.

Clostridium botulinum and Listeria contamination found in multiple food products, including vegetables, mushrooms, and seafood chowders.

Onyema Ogbuagu, MBBCh, FACP, FIDSA discussed 96% virologic suppression with lenacapavir-based therapy, showing similar results to daily oral regimens.

Anchalee Avihingsanon, MD, PhD presents results showing 95.4% HIV RNA suppression and 86.6% HBV DNA suppression after 48 weeks of B/F/TAF in HIV-HBV co-infected patients.

David Berman, MD, PhD, discusses signs of dose-dependent viral control and reduction in active HIV reservoir in Phase 1/2 STRIVE trial data.

Phase 1 data on VH184, a third-generation integrase strand transfer inhibitor, and VH499, a novel HIV-1 capsid inhibitor, highlighting their antiviral potency, safety profiles, and potential for long-acting injectable formulations.